MedTrace Logo

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

NCT05303376 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2023-09-13

No results posted yet for this study

Summary

This is a Phase 1 and phase 2, adaptive, placebo-controlled, double-blind, randomized single-dose study in participants with Severe COVID-19 illness.

Conditions

Interventions

BIOLOGICAL

IBIO123

5 or 10 mg

OTHER

Placebo

matching placebo

Sponsors & Collaborators

  • Immune Biosolutions Inc

    lead INDUSTRY

Principal Investigators

  • Sebastien Labbe, PhD · Immune Biosolutions

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2023-06-27
Completion
2023-06-27

Countries

  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05303376 on ClinicalTrials.gov